Sulfonylureas, Secretor, Stimulates production/release of insulin from pancreas, lowers BS, MAJOR HYPOGLYCEMIA SIDE EFFECT, Related to Sulfonamides (antibacterial meds) avoid if allergic to sulfa drugs, Become less effective over time and may cause some weight gain, a potential problem for the overweight pt., Glipizide (Glucotrol), Glimepiride (Amaryl), Glyburide (Micronase, Diabeta), Non-sulfonylurea insulin secretagogues (Meglitinides), Secretor (shorter 1/2 life than Sulf), Stimulate the pancreas to produce insulin rapidly in response to eating and target post-prandial BS, hypoglycemia if meal skipped, Take from 30 minutes before meal up to actual meal time; do not take if meal is skipped, Rapid-acting, works w/ meal, if meal skipped, skip dose, metabol in 3 to 6 hrs, dec risk of pre-pran hypoglyc eps, Repaglinide (Prandin), Nateglinide (Starlix ), SGLT2 inhibitor, transporter, Block reabsorption of glucose in kidneys, results in more glucose excreted in urine, uti, genital infections, hypoglycemia, caution in renal disease, reduces BP, used in heart failure, Canagliflozin (Invokana); dapagliflozin (Farxiga); empagliflozin (Jardiance), Thiazolidinediones (glitazones), Sensitize body tissues to insulin, simulates insulin receptor sites of the cells to improve action of insulin., Risk of hypoglycemia especially if used with insulin or other antidiabetic agent, decrease effectivness of oral contrecept., Pioglitaxone (Actos) and Rosiglitazone (Avandia), Synthetic Amylin Analog, hormone, Slows gastric emptying (satiety), slows hepatic glucose prod (lower post meal BS and contributes to weight loss), used in addition to mealtime insulin in patients with type 1 or type 2 diabetes. Can cause Hypoglycemia (DM 1), NO patient with gastroparesis, Only used with insulin; does not replace insulin; Patients must ensure all meals contain at least 250 calories or 30 gms of CHO while on therapy., Pramlintide (Symlin)
0%
med
Kongsikan
Kongsikan
oleh
Angelnursingcchs
Edit Kandungan
Cetakan
Benamkan
Lebih lagi
Tugasan
Papan mata
Paparkan banyak
Paparkan sedikit
Papan mata ini berciri peribadi pada masa ini. Klik
Kongsikan
untuk menjadikannya umum.
Papan mata ini telah dilumpuhkan oleh pemilik sumber.
Papan mata ini dinyahdayakan kerana pilihan anda berbeza daripada pemilik sumber.
Pilihan untuk Kembali
Susunan kumpulan
ialah templat terbuka. Ia tidak menjana skor untuk papan mata.
Log masuk diperlukan
Gaya visual
Fon
Langganan diperlukan
Pilihan
Tukar templat
Paparkan semua
Buka keputusan
Salin pautan
Kod QR
Padam
Pulihkan autosimpan:
?